Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 24:6:167-77.
doi: 10.2147/vhrm.s4551.

Advances in the treatment of Raynaud's phenomenon

Terri L Levien  1
Affiliations
Review

Advances in the treatment of Raynaud's phenomenon

Terri L Levien. Vasc Health Risk Manag. .

Abstract

Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.

Keywords: Raynaud; bosentan; iloprost; phosphodiesterase-5 inhibitors.

PubMed Disclaimer

References

    1. Wigley FM. Raynaud’s phenomenon. N Engl J Med. 2002;347:1001–1008. - PubMed
    1. Cooke JP, Marshall JM. Mechanisms of Raynaud’s disease. Vasc Med. 2005;10:293–307. - PubMed
    1. Bakst R, Merola JE, Franks AG, Jr, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59:633–653. - PubMed
    1. Rosenkranz S, Diet F, Karasch T, Weibrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon [letter] Ann Intern Med. 2003;139:871–872. - PubMed
    1. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–2985. - PubMed

MeSH terms